<DOC>
	<DOCNO>NCT02134015</DOCNO>
	<brief_summary>1 . Part A : Subjects receive Patritumab placebo erlotinib . Progression-free survival primary outcome . Subjects need Epidermal Growth Factor Receptor ( EGFR ) wild-type , locally advance metastatic NSCLC cancer progress least one prior systemic anti-cancer therapy , available recent archival tumor specimen may previous EGFR-targeted regimen , anti-HER2 ( Human Epidermal Growth Factor Receptor 2 ) , anti-HER3 , anti-HER4 therapy . Subjects may high heregulin low heregulin . 2 . Part B : Subjects receive Patritumab placebo erlotinib . Overall survival primary outcome . Subjects need EGFR wild-type , locally advance metastatic NSCLC cancer progress least one prior systemic anti-cancer therapy , available recent archival tumor specimen may previous EGFR-targeted regimen , anti-HER2 , anti-HER3 , anti-HER4 therapy . Only subject high heregulin enrol .</brief_summary>
	<brief_title>Study Patritumab Combination With Erlotinib Subjects With Locally Advanced Metastatic Non-Small-Cell Lung Cancer ( NSCLC ) . ( HER3-Lung )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Must great equal 20 year age 2 . Must cytologically histologically confirm NSCLC either : Metastatic disease ( Stage IV ) OR Stage IIIB disease amenable surgery curative intent . Note : It permissible use either AJCC Version 6.0 AJCC Version 7.0 stag system . For site use AJCC Version 7.0 , T4M0 patient ipsilateral nodule N0N2 still eligible . 3 . If tumor histology adenocarcinoma , must wildtype EGFR genotype assess validated assay include exon 19 deletion exon 21 ( L858R ) substitution . 4 . Must receive one two prior line systemic chemotherapy advance metastatic disease , one must platinumdoublet therapy . 5 . Must disease progression recurrence document radiographic assessment follow treatment last chemotherapy chemoradiation regimen ( complete within previous 12 month ) . 6 . Must available recent ( treatment start ) archival tumor specimen . 7 . Must measurable disease Part A , measurable disease nonmeasurable disease Part B 8 . Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 9 . Must adequate hematological function 10 . Must adequate renal function 11 . Must adequate hepatic function 12 . Agreement use effective contraception treatment least 6 month end treatment 13 . Must provide informed consent study participation . 1 . Lung adenocarcinoma Anaplastic Lymphoma Kinase ( ALK ) gene rearrangement 2 . Left ventricular ejection fraction ( LVEF ) less 45 % 3 . Prior EGFRtargeted regimen , antiHER2 , antiHER3 , antiHER4 therapy 4 . History malignancy , except adequately treat nonmelanoma skin cancer , curatively treat insitu disease , solid tumor curatively treat evidence disease great equal 5 year 5 . History corneal disease 6 . History interstitial lung disease ( ILD ) 7 . Clinically active brain metastasis 8 . Uncontrolled hypertension 9 . Clinically significant ECG change 10 . Clinically significant ( opinion Investigator ) ascites pleural effusion require chronic medical intervention 11 . Myocardial infarction within 1 year enrollment , symptomatic congestive heart failure , unstable angina , unstable cardiac arrhythmia require medication 12 . Treatment anticancer therapy , antibodybased therapy , retinoid therapy , hormonal therapy within 4 week study drug treatment 13 . Therapeutic radiation therapy major surgery within 4 week study drug treatment ; palliative radiation within 2 week study drug treatment 14 . Participation clinical drug trial within 4 week 15 . Uncontrolled infection require IV antibiotic , antiviral , antifungal , know human immunodeficiency virus ( HIV ) infection , active hepatitis B C infection . 16 . History hypersensitivity study drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Non-Small-Cell Lung</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Bronchogenic</keyword>
	<keyword>Bronchial Neoplasms</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>